Otaplimastat SP-8203|cas:1176758-04-5|西域试剂

Otaplimastat SP-8203,98.41%

产品编号：Bellancom-109097| CAS NO：1176758-04-5| 分子式：C₂₈H₃₄N₆O₅| 分子量：534.61

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-109097	￥3000.00	杭州北京（现货）
Bellancom-109097	￥4800.00	杭州北京（现货）
Bellancom-109097	￥9500.00	杭州北京（现货）
Bellancom-109097	￥14500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Otaplimastat SP-8203

产品介绍

Otaplimastat (SP-8203) 是一种基质金属蛋白酶 (MMP) 抑制剂，以竞争方式阻断 NMDA 受体介导的兴奋性毒性。Otaplimastat 还具有抗氧化活性。Otaplimastat 可用于脑缺血损伤的研究。

生物活性

Otaplimastat (SP-8203), a matrix metalloproteinase (MMP) inhibitor, blocks N-methyl-D-aspartate (NMDA) receptor-mediated excitotoxicity in a competitive manner. Otaplimastat also exhibits anti-oxidant activity. Otaplimastat can be used for the research of brain ischemic injury.

体外研究

Otaplimastat (87.5-350 μM; 20 min) protects neuronal cells against NMDA-induced cell death in a competitive manner.
Otaplimastat (350 μM) inhibits Ca²⁺ influx following activation of NMDA receptors in primary cultured neuron.
Otaplimastat (2-200 μM; pretreated for 4 h) significantly suppresses H₂O₂-induced cell death and reactive oxygen species production.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Otaplimastat (10-20 mg/kg; i.p. 30 min before occlusion and 1 h after reperfusion) prevents ischemic neuronal death in the occlusion model of MCA.
Otaplimastat (5-10 mg/kg; i.p. daily for 10 days) attenuates impairment of stroke-induced motor function.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Wistar rats (280-310 g, 9 weeks) were induced transient middle cerebral artery (MCA) occlusion
Dosage:	10, 20 mg/kg
Administration:	I.p. before 30 min and after an hour of the MCA-occlusion operation
Result:	Significantly reduced infarct volume. Improved spatial learning and memory impairments.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Wistar rats (280-310 g, 9 weeks) were induced transient middle cerebral artery (MCA) occlusion
Dosage:	10, 20 mg/kg
Administration:	I.p. before 30 min and after an hour of the MCA-occlusion operation
Result:	Significantly reduced infarct volume. Improved spatial learning and memory impairments.

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (187.05 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.8705 mL	9.3526 mL	18.7052 mL
5 mM	0.3741 mL	1.8705 mL	3.7410 mL
10 mM	0.1871 mL	0.9353 mL	1.8705 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式